DTIL PRECISION BIOSCIENCES INC

Price Chart

Executive Summary

Precision BioSciences announced new and late-breaking clinical data from the Phase 1 ELIMINATE-B trial of PBGENE-HBV in chronic hepatitis B at the EASL Congress 2026. Liver biopsy data showed a 1-log (10-fold) reduction in cccDNA-derived transcripts, the first-ever clinical evidence of direct cccDNA elimination by a therapeutic agent, and 100% of patients with detectable pgRNA at baseline achieved pgRNA loss. The safety profile was manageable with no dose-limiting toxicities, though Grade 3 hypotension and ALT/AST abnormalities were observed and mitigated with protocol adjustments.

Actionable Insight

Key Facts

• Liver biopsy data demonstrated a 1-log (10-fold) reduction in cccDNA-derived transcripts after two doses at 0.4 mg/kg, the first clinical evidence of direct cccDNA elimination by a therapeutic agent.
• PBGENE-HBV achieved pgRNA loss in 100% of patients (n=6) with detectable pgRNA at baseline, with complete loss of blood pgRNA corresponding to undetectable pgRNA in post-treatment liver biopsy.
• 100% of patients (n=15) experienced substantial HBsAg declines across all dose levels, with durable response ranging from 1.5 to 12+ months in patients who received repeat administrations (n=13).
• As of data cutoff (May 4, 2026), 38 doses were administered across 16 patients in 5 cohorts; no dose-limiting toxicities were observed.
• Grade 3 hypotension and reversible ALT/AST abnormalities were observed but mitigated with slower infusion rates and increased steroid doses; no Grade 3 events occurred after mitigation protocol implementation in up to 20% of doses.
• PBGENE-HBV has FDA Fast Track designation; next update expected by end of 2026 with expansion into Part 2 of the trial.

Financial Impact

No financial figures reported; clinical-stage company with no revenue from PBGENE-HBV. Positive clinical data could significantly increase probability of regulatory success and partnership value.

Risk Factors

• Small sample size (n=16) limits statistical robustness; results may not replicate in larger populations.
• One patient in the highest dose cohort (0.8 mg/kg) experienced two serious adverse events, including a treatment-related hypotension event.
• Long-term durability of viral cure and functional cure endpoints (HBsAg loss, nucleoside analog withdrawal) remain unproven.
• Competing gene editing and antiviral approaches may achieve similar or better results.
• Company has no approved products and relies on capital markets for funding; positive data may accelerate but does not eliminate financing risk.

Market Snapshot

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

US Market Status